178 results on '"Nisar, Muhammad K."'
Search Results
2. Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active disease
3. P107 Real world clinical outcomes of patients with moderate-to-severe rheumatoid arthritis initiating upadacitinib in the United Kingdom: Interim analysis from a prospective observational cohort study (ENDEAVOUR)
4. Cupping (Hijama) Treatment : Benign or Sinister?
5. Adherence to biologic therapy – Does it vary with ethnicity?
6. Early arthritis service is cost-effective, improves outcomes and reduces biologic use
7. Pulmonary Complications of Biological Therapies in Children and Adults with Rheumatic Diseases
8. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom
9. P118 Drive-through phlebotomy - is this the future?
10. Biomarkers Predict In-Hospital Major Adverse Cardiac Events in COVID-19 Patients: A Multicenter International Study
11. What do we know about juvenile idiopathic arthritis and vitamin D? A systematic literature review and meta-analysis of current evidence
12. Same-day or historical ESR for disease activity score measurement: does it matter?
13. Interleukin-6 and cytochrome-P450, reason for concern?
14. Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review
15. Biomarkers predict in-hospital major adverse cardiac events in covid-19 patients : A multicenter international study
16. TNF antagonists and shingles: is vaccination advisable?
17. Comment on: Non-infectious pulmonary toxicity of rituximab: a systematic review: reply
18. Musculoskeletal examination and junior doctors: cause for concern?
19. Non-infectious pulmonary toxicity of rituximab: a systematic review
20. The role of tocilizumab monotherapy in the management of rheumatoid arthritis: a review
21. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases—a systematic literature review
22. A challenging case of gout and failure of anti-TNF therapy- Are current treatments adequate?
23. P272 How well are conventional DMARDs tolerated in PsA: a real-world study
24. EP43 Biologic retention in psoriatic arthritis: a real world study
25. P114 Which antibody is more important for radiographic erosions in RA?
26. P89 Can we manage osteoporosis without patients ever seeing a consultant?
27. EP22 Teriparatide use in the real world: can we expect cost savings with a switch to generic version?
28. EP15 Switching to biosimilar adalimumab: a real world study
29. Disease remission the goal of therapy in rheumatoid arthritis
30. Combining secukinumab and fingolimod to successfully treat ankylosing spondylitis and multiple sclerosis – A novel approach
31. 071 Does biologic retention vary with methotrexate co-prescription dose in established RA? A real world study
32. 147 Do dedicated early arthritis clinics improve psoriatic arthritis outcomes? A real world study
33. 122 Secukinumab and solid organ cancer: are they mutually exclusive?
34. 121 Combining secukinumab and fingolimod to successfully treat ankylosing spondylitis and multiple sclerosis: a novel approach
35. 204 Switching to biosimilar rituximab: a real world study
36. 180 Does the quality & outcomes framework (QOF) indicator for osteoporosis work? A primary care study
37. E028 Rituximab biosimilar and miliary tuberculosis: vigilance is the key
38. Lemierre’s syndrome: a rare cause of septic polyarthritis
39. BHPR research: qualitative1. Complex reasoning determines patients' perception of outcome following foot surgery in rheumatoid arhtritis
40. Rheumatoid arthritis - clinical aspects: 134. Predictors of Joint Damage in South Africans with Rheumatoid Arthritis
41. Giant Cell Hepatitis – A Rare Association with Connective Tissue Disease
42. 014 Combining secukinumab and apremilast to successfully treat refractory psoriatic skin and joint disease: a novel approach
43. e03 ACTH reborn: modernising the evidence
44. e34 Is the dose banding of infliximab cost effective? A real world study
45. 317 BSR DMARD guidelines and shared prescribing in primary care: is it reliable?
46. 292 Switching to biosimilar rituximab: a real world study
47. 071 Do dedicated early arthritis clinics improve patient outcomes? A real world study
48. 274 Rheumatology nurse specialists and corticosteroid prescribing: is it safe?
49. 015 Giant cell hepatitis with CTD and ILD: mycophenolate mofetil treating an elusive multi system disease
50. 267 Can community pharmacy services help early identification of psoriatic arthritis? A novel proof of concept study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.